Diagnosis and Treatment Guidelines for Mesenchymal Stem Cell Therapy for Coronavirus Disease 2019(Beijing,2021)
Diagnosis and Treatment Guidelines for Mesenchymal Stem Cell Therapy for Coronavirus Disease 2019 (Beijing, 2021)作者机构：Department of Infectious DiseasesFifth Medical Center of Chinese PLA General HospitalNational Clinical Research Center for Infectious DiseasesBeijing 100039China Department of GastroenterologyChangzheng Hospital of the Second Military Medical UniversityShanghai 200001China Department of Medical StatisticsPeking University First HospitalBeijing 100191China National Industrial Base for Stem Cell Engineering ProductsTianjin 300384China Department of Cardiac SurgeryShanghai East HospitalTongji UniversityShanghai 310000China Office of Clinical Evaluation of Biological ProductsCenter for Drug EvaluationChina Food and Drug AdministrationBeijing 100053China China Medicinal Biotech AssociationBeijing 100022China National Cell Collection and Research CenterInstitute for Biological Product ControlNational Institutes for Food and Drug ControlTiantanXiliDongcheng DistrictBeijing 100050China State Key Laboratory for Diagnosis and Treatment of Infectious DiseasesNational Clinical Research Center for Infectious DiseasesCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseasesthe First Affiliated HospitalCollege of MedicineZhejiang UniversityHangzhou 310003China Department of Infectious Diseases and the Center for Liver DiseasesPeking University First HospitalBeijing 100034China Department of Infectious DiseasesPeking Union Medical College HospitalPeking Union Medical CollegeChinese Academy of Medical SciencesBeijing 100730China Radiology DepartmentPeking University First HospitalBeijing 100034China JOINN Laboratories(Beijing)Beijing 100176China Chinese Center for Disease Control and PreventionBeijing 102206China Department of Infectious DiseasesHuashan HospitalShanghai Medical CollegeFudan UniversityShanghai 200040China CAS Key Laboratory of Microbial Physiological and Metabolic EngineeringState Key Laboratory of Microbial ResourcesInstitute of MicrobiologyChinese Academy of SciencesBeijing 100730China Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China The State Key Laboratory of Experimental HematologyNational Clinical Research Center for Blood DiseasesInstitute of Hematology and Blood Diseases HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeTianjin 300020China Laboratory of Aging Research and Cancer Drug TargetState Key Laboratory of Biotherapy and Cancer CenterNational Clinical Research Center for GeriatricsWest China HospitalSichuan UniversityChengdu 610041China State Key Laboratory of Stem Cell and Reproductive BiologyNational Stem Cell Resource CenterInstitute of ZoologyChinese Academy of SciencesBeijing 100101China Beijing Institute for Stem Cell and Regenerative MedicineBeijing 100101China
出 版 物：《Infectious Diseases & Immunity》 (感染性疾病与免疫（英文）)
年 卷 期：2021年第1卷第2期
页 面：68-73页
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
基 金：This work was supported by The National Key R&D Program of China(Nos.2020YFC0841900,2020YFC0844000,and 2020YFC08860900) The Innovation Groups of the National Natural Science Foundation of China(No.81721002) Study on Comprehensive Treatment of Pneumonia(No.BWS20J006)
主 题：COVID-19 Mesenchymal stem cell Treatment
摘 要：The coronavirus disease 2019(COVID-19)can be caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection,and has led to millions of deaths among more than 100 million infected people around the world according to the declaration from World Health *** immune response of both the innate and adaptive immune systems is subsistent on COVID-19 patients,of which the degree are associated with disease severity,lung damage and long term functional *** treatment options have included antiretroviral drugs,anti-inflammatory factors,antibodies,immune checkpoint inhibitors,and convalescent plasma *** recently,mesenchymal stem cell(MSC)therapy has been explored for the management and control of COVID-19,particularly with the aim of preventing or at least mitigating respiratory *** the safety and efficacy of stem cell therapy have been validated in multiple phase I–III clinical trials,to date,no standardized stem cell preparation,administration dosage or interval,product QA/QC testing,storage,transportation,or disposal protocols have been *** present paper proposes a systematic methodology that addresses all the foregoing process steps and evaluation criteria for the efficacious and safe administration of MSCs in the treatment of patients infected with COVID-19.
维普期刊数据库